%0 Journal Article
%T Treatment of Patients with ALK-positive Non-small Cell Lung Cancer £¿and Brain Metastases
%A Jialin LV
%A Quan ZHANG
%A Na QIN
%A Xinjie YANG
%A Xinyong ZHANG
%A Yuhua WU
%A Xi LI
%A Hui ZHANG
%A Jinghui WANG
%A Shucai ZHANG
%J Öйú·Î°©ÔÓÖ¾
%D 2016
%R : 10.3779/j.issn.1009-3419.2016.08.06
%X Background and objective Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) is an important subtype of lung cancer. The standard modality of ALK-positive NSCLC with brain metastases remains uncertain. Methods We collected data on clinical characteristics and treatment of patients with ALK-positive NSCLC and brain metastases between March 2013 and March 2016 and retrospectively analyzed patient outcomes. Results In 84 ALK-positive patients with advanced NSCLC, 22 (26.2%) had brain metastases during the initial diagnosis of lung cancer, among which 3 patients with EGFR mutation were excluded, and 19 patients were analyzed. Median intracranial progression-free survival (PFS) was 12.0 months. PFS for patients who received first-line local brain therapy (P=0.021) and crizotinib therapy (P=0.030) was superior to PFS for patients without such therapies. PFS for patients who received first-line crizotinib combined with local brain therapy was 27.0 months and only 4.2 months for those who received crizotinib alone. Conclusion First-line crizotinib therapy combined with local brain treatment can improve intracranial PFS for ALK-positive NSCLC with brain metastases. This finding should be confirmed further through multicenter, prospective clinical trials with large sample size.
%K Lung neoplasms
%K ALK
%K Brain metastases
%U http://www.lungca.org/index.php?journal=01&page=article&op=view&path%5B%5D=10.3779%2Fj.issn.1009-3419.2016.08.06